Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2020
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering.
Key Financial Metrics
This filing reports on a specific capital raising event rather than periodic financial performance. Key metrics related to the transaction include:
- Shares Sold: 14,634,146 shares of Common Stock.
- Offering Price: $0.41 per share.
- Gross Proceeds: Approximately $6.0 million.
- Placement Fees: 8% of gross proceeds paid to Lake Street Capital Markets, LLC and Ladenburg Thalmann & Co. Inc.
- Expense Reimbursement: Up to $50,000 for placement agent expenses.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transaction-specific report.
Material Changes
The primary material change is the execution of a securities purchase agreement on June 29, 2020, resulting in the issuance of new common stock. This transaction increases the company's share count and cash position (net of fees) but does not report comparative financial changes against a prior period.
Guidance, Outlook, and Risks
Management Commentary: The offering was conducted pursuant to an effective shelf registration statement (Form S-3) and a prospectus supplement dated June 29, 2020.
Risks and Contingencies: The Purchase Agreement includes customary representations, warranties, conditions to closing, indemnification obligations, and termination provisions. The filing incorporates the full agreement by reference for detailed terms.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 8% placement fee and up to $50,000 in reimbursable expenses.
- Confirm the updated total share count and potential dilution impact on existing shareholders.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Check the press release (Exhibit 99.1) for the stated intended use of the raised capital.